Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

IGH/MYC Translocation in Burkitt Lymphoma Is Associated with BRCA2 Deficiency and Synthetic Lethality By PARP1 Inhibitors

Silvia Maifrede, Kayla Martin, Paulina Podszywalow-Bartnicka, PhD, Sullivan Katherine, Samantha Langer, Reza Nejati, Yashodhara Dasgupta, Daniel Gritsyuk, Margaret Nieborowska-Skorska, Lena Lupey, Katarzyna Piwocka, Mariusz A Wasik, MD, Italo Tempera, Tomasz Skorski

Blood (2016) 128 (22): 4111.

https://doi.org/10.1182/blood.V128.22.4111.4111

Published: 2016

Journal Articles

Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells

Marco Ruella, MD, Michael Klichinsky, PharmD, Saad S Kenderian, MD, Olga Shestova, PhD, Amy Ziober, Michael D Feldman, MD, Mariusz A Wasik, MD, Carl H June, MD, Saar I Gill, MBBS, PhD

Blood (2016) 128 (22): 43.

https://doi.org/10.1182/blood.V128.22.43.43

Published: 2016

Journal Articles

Treatment with Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) Results in Durable Remissions in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphomas of Germinal Center and Non-Germinal Center Origin, "Double Hit" Diffuse Large B Cell Lymphomas, and Transformed Follicular to Diffuse Large B Cell Lymphomas

Stephen J. Schuster, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, Elise A. Chong, MD, Nicole Winchell, Daniel J. Landsburg, MD, David L. Porter, MD, Anthony R. Mato, MD, Honore T Strauser, April M. Schrank-Hacker, Mariusz A Wasik, MD, Simon Francis Lacey, PhD BS, Jan Joseph Melenhorst, PhD, Anne Chew, PhD, Jens Hasskarl, MD PhD, Katherine T. Marcucci, PhD, Bruce L Levine, PhD, Carl H June, MD

Blood (2016) 128 (22): 3026.

https://doi.org/10.1182/blood.V128.22.3026.3026

Published: 2016

Journal Articles

Kinase Inhibitor Ibrutinib Prevents Cytokine-Release Syndrome after Anti-CD19 Chimeric Antigen Receptor T Cells (CART) for B Cell Neoplasms

Marco Ruella, MD, Saad S Kenderian, MD, Olga Shestova, PhD, Michael Klichinsky, PharmD, J. Joseph Melenhorst, PhD, Mariusz A Wasik, MD, Simon F. Lacey, PhD, Carl H June, MD, Saar I Gill, MBBS, PhD

Blood (2016) 128 (22): 2159.

https://doi.org/10.1182/blood.V128.22.2159.2159

Published: 2016

Journal Articles

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Engraftment and Antitumor Responses Against Mantle Cell Lymphoma

Marco Ruella, MD, Saad S Kenderian, MD, Olga Shestova, PhD, Joseph A. Fraietta, PhD, Sohail Qayyum, MD, Qian Zhang, MD PhD, Marcela V. Maus, MDPhD, Xiaobin Liu, PhD, Selene Nunez-Cruz, PhD, Michael Klichinsky, PharmD, Omkar Uday Kawalekar, MS, BS, Michael C. Milone, MD PhD, Simon F. Lacey, PhD BSc, Anthony Mato, MD, Stephen J. Schuster, MD, Michael Kalos, PhD, Carl H. June, MD, Saar I Gill, MBBS, PhD, Mariusz A. Wasik, MD

Blood (2015) 126 (23): 704.

https://doi.org/10.1182/blood.V126.23.704.704

Published: 2015

Journal Articles

Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas

Stephen J. Schuster, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, David L. Porter, MD, Elise A. Chong, MD, Daniel J. Landsburg, MD, Anthony R. Mato, MD MSCE, Simon F. Lacey, PhD BS, Jan J. Melenhorst, PhD, Anne Chew, PhD, Jens Hasskarl, MD PhD, Gaurav D. Shah, MD, Mariusz A. Wasik, MD, Katherine T. Marcucci, PhD, Zhaohui Zheng, MS, Bruce L. Levine, PhD, Carl H. June, MD

Blood (2015) 126 (23): 183.

https://doi.org/10.1182/blood.V126.23.183.183

Published: 2015

Journal Articles

Novel Chimeric Antigen Receptor T Cells for the Treatment of Hodgkin Lymphoma

Marco Ruella, MD, Saad S Kenderian, MD, Olga Shestova, PhD, Taylor Chen, John Scholler, Mariusz A. Wasik, MD, Carl H. June, MD, Saar I. Gill, MD PhD

Blood (2014) 124 (21): 806.

https://doi.org/10.1182/blood.V124.21.806.806

Published: 2014

Journal Articles

Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas

Blood (2014) 124 (21): 3087.

https://doi.org/10.1182/blood.V124.21.3087.3087

Published: 2014

Journal Articles

Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells

Noelle V. Frey, MDMS, Bruce L. Levine, PhD, Simon F. Lacey, PhD BSc, Stephan A. Grupp, MD PhD, Shannon L Maude, MD PhD, Stephen J. Schuster, MD, Pamela Shaw, PhD, Wei-Ting Hwang, PhD, Mariusz A. Wasik, MD, Amrom Obstfeld, MD, Mimi Leung, MPH, Angela Shen, MD, Solveig G. Ericson, MD PhD, Jan J Melenhorst, PhD, Carl H. June, MD, David Porter, MD

Blood (2014) 124 (21): 2296.

https://doi.org/10.1182/blood.V124.21.2296.2296

Published: 2014

Journal Articles

Stat5a Is Epigenetically Silenced by Oncogenic Tyrosine Kinase NPM/ALK and Acts as Tumor Suppressor by Reciprocally Inhibiting Expression of NPM/ALK.

Qian Zhang, MD, PhD, Hong Yi Wang, PhD, XiaoBin Liu, Ms, Mariusz A. Wasik, MD

Blood (2007) 110 (11): 4170.

https://doi.org/10.1182/blood.V110.11.4170.4170

Published: 2007

NARROW

IGH/MYC Translocation in Burkitt Lymphoma Is Associated with BRCA2 Deficiency and Synthetic Lethality By PARP1 Inhibitors

Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells

Kinase Inhibitor Ibrutinib Prevents Cytokine-Release Syndrome after Anti-CD19 Chimeric Antigen Receptor T Cells (CART) for B Cell Neoplasms

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Engraftment and Antitumor Responses Against Mantle Cell Lymphoma

Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas

Novel Chimeric Antigen Receptor T Cells for the Treatment of Hodgkin Lymphoma

Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas

Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells

Stat5a Is Epigenetically Silenced by Oncogenic Tyrosine Kinase NPM/ALK and Acts as Tumor Suppressor by Reciprocally Inhibiting Expression of NPM/ALK.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only